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1. Pain
Pain is one of the most common ailments which drive patients to a clinic, and pain alleviation 
is a key factor in the understanding of the well-being. There is a heightened awareness of 
pain as the “fifth vital sign,” therefore it should be monitored as cautiously as blood pressure, 
temperature, respiratory rate, and pulse. This also entails a change in paradigm, which means 
pain treatment has shifted from decisions taken by an individual physician with an unspeci-
fied follow-up to more systematic approach by multidisciplinary teams [1, 2].
Pain is defined by WHO as “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage.” The inclusion 
of the word “emotional” is crucial for the understanding of the implications of pain percep-
tion by a subject. The obvious consequence of this is that that pain perception is unique to 
each individual, as well as pain threshold is different in subjects. Cultural aspects should 
also be considered as it is nowadays preconized that no one should experience pain, not even 
when giving birth. Pain is culturally determined and cannot be defined so coarsely when it 
has so many influencing factors on how it is apprehended and expressed, being culture one 
of the most efficacious ones [3–6]. The clinician should then make a great effort to conceptu-
alize pain in the search for pain alleviation because pain relieving is one of the main goals 
in practice.
Even though it is an ailment common to many diseases and medical procedures and in many 
cases, an illness in itself, it is not common to find a specialization on pain in medical schools. 
In general, pain management or pain medicine should entail, though not always does, a mul-
tidisciplinary approach for easing the suffering and improving the quality of life of those 
patients suffering from it [2, 7–9].
Although it may not be correct, it is possible to distinguish between acute and chronic pain. 
The first one has gained more attention because the success in its treatment, due to advances in 
pharmacology, and also because it is generally easily associated with a biomedical pathological 
cause. It is also in this kind of pain that neurophysiological explanations are fundamental for 
its understanding [10].
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In acute pain, a pharmacological approach is usually successful in the treatment because in 
general a biological approximation to the matter is acceptable. Collectively, non-steroidal 
anti-inflammatory agents (NSAIDs) and acetaminophen (paracetamol) are the most com-
monly used pain medications, followed by opioids generally used in moderate to severe pain 
[11, 12].
The definition aforementioned is not adequate for chronic pain because chronic pain does not 
only entail a biological state but also a psychological one, which in many cases is able to con-
trol patients’ lives. An ordinary approximation to chronic pain would give us a false impres-
sion that it can be successfully treated by the ample arsenal of drugs available; however, in 
many aspects, chronic pain is still an enigma for medicine. Chronic pain may be defined 
then as a state of sensitized perception of pain that exceeds the simple sensorial experience. 
Medicine treats injury and pathology to support and speed healing and treats distressing 
symptoms such as pain to relieve suffering during treatment and healing. When a painful 
injury or pathology is resistant to treatment, when pain persists after the injury or pathol-
ogy has healed, and when medical science cannot identify the cause of pain, the task faced is 
much more difficult. The obvious consequence of this is that treatment approaches to chronic 
pain not only include pharmacologic measures, such as analgesics, tricyclic antidepressants, 
and anticonvulsants but also interventional procedures, physical therapy, and psychological 
measures [10, 13–16]. As a consequence of this, the typical chronic pain management team 
includes anesthesiologists, occupational therapists, physiotherapists, clinical psychologists, 
and pain nurses. Together the multidisciplinary team can help create a package of care suit-
able to the patient. While acute pain usually resolves once the underlying trauma or pathology 
has healed and is treated by one practitioner, effective management of chronic pain frequently 
requires the coordinated efforts of multiple disciplines [14].
2. Pain treatment
In the last decades, the understanding of the multiple mechanisms and molecules that under-
lie pain perception have turned its treatment into a puzzle formed by therapies that involve 
not only the common substances considered as analgesics (NSAIDS and opioids) but also a 
wide array of other drugs such as anticonvulsants and antidepressant and not less impor-
tant manual techniques, together with psychological follow-up, which has also proved to be 
successful in containing patients emotionally [10, 12–14]. The understanding of the different 
routes involved in this complex phenomenon has opened its therapy not only to drugs, not 
previously considered as analgesics, but also to the development of pharmaceutical forms able 
to alleviate pain for long periods of time as well as electrical techniques for the interruption of 
pain signal transduction [13, 14, 17].
Even though medicines seem to be the most common resource for pain relief, and despite all 
the advances in pain understanding, many people still restore to nontraditional or alternative 
medicine, some forced by the high costs of health care and others pushed by the inefficacy of 
conventional treatments [18].
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2.1. Analgesics
The word analgesic derives from Greek an- (ἀν-, “without”), álgos (ἄλγος, “pain”), and -ikos 
(-ικος, forming adjectives). Such drugs were usually known as anodynes before the twentieth 
century.
Both broader classes of analgesics have a natural origin. Salicylic acid extracted from the bark of 
Willow tree gave birth to NSAIDs, whereas Papaver somniferum is the origin of opioids [19, 20].
The mechanism of action shown by acetylsalicylic acid was at first generalized to all NSAIDs; 
however, nowadays this group comprises diverse classes of structures which have demon-
strated different potential as anti-inflammatory, antipyretic, and analgesic drugs. In the last 
century, acetaminophen has gained field in treatment of mild pain, but it is still nowadays stud-
ied regarding its mechanism of action as it seems not to be like any other kind of analgesic [21].
The long use of these substances has allowed a thorough study of their efficacy as well as their 
safety profile; however, in many countries NSAIDs being sold as over-the-counter drugs, give 
the false impression of innocuous products when in fact they are not [22, 23].
NSAIDs differ from acetaminophen in that they possess anti-inflammatory properties and 
are associated with a different side effect profile that includes bleeding, gastrointestinal ulcer-
ation, renal dysfunction, and an elevated risk of adverse cardiovascular events. On the other 
hand, paracetamol, though a widespread option for mild pain, rises concerns regarding its 
safety in people with impaired hepatic function, alcoholics, etc. [24–26].
Morphine derivatives are in general more cautiously used, and in the last decades, attitude 
toward opioids has shifted from willingness to fear of their use especially because of their 
potential for addiction which leads to the prescription of lower than effective doses.
In many settings, morphine is still the standard of care in active cancer because of its short 
half-life, which allows a more flexible administration regimen. The availability of multiple 
pharmaceutical dosage forms and, last but not least, economic reasons have maintained 
morphine as a current option [27–29]. In contrast, the long-term administration of an opioid 
for the treatment of chronic noncancer pain continues to be controversial accompanied by 
the folk knowledge that sustains the use of opioids in terminal illnesses [30–32]. In this set-
ting, opioids, such as tramadol, methadone, and oxycodone, have gained field to morphine 
because of either their more advantageous pharmacokinetics parameters or the addition of 
adjunctive mechanisms of action (serotonin, norepinephrine reuptake inhibition, and NMDA 
antagonism).
Even though opioids are the first-line approach for moderate or severe pain in populations 
with active cancer, the comprehensive management of pain in this kind of patient also requires 
expertise in the use of the nonopioid analgesics, such as acetaminophen (paracetamol), non-
steroidal anti-inflammatory agents (NSAIDs), and drugs referred to as “adjuvant” analgesics 
or coanalgesics [33].
The knowledge that serotonin and norepinephrine play an important role in pain has influ-




wide array of drugs for pain alleviation. SNRIs are commonly used in conjunction with opi-
oids (especially tapentadol and tramadol) with greater success in pain relief. This is the case 
of chronic pain syndromes, which usually require the use of this “adjuvant analgesics.” The 
treatment of neuropatic pain has changed with time. At the beginning it included tricyclic 
antidepressants and anticonvulsants such as carbamazepine. Nowadays, the arsenal has 
spread with the use of gabapentinoids and SNRI antidepressants, such as duloxetine which in 
recent years has acquired approved indications for pain. For migraine pain, anticonvulsants 
such as valproic acid and topiramate are also used [34, 35]. And last but not least the T-type 
calcium channel blockers have also been included in pain treatment protocols in animals and 
human models [36–39].
2.2. Other targets and techniques for pain alleviation
When Western medicines seem not to be effective, many people restore to nontraditional or 
alternative medicine. There is some evidence that some treatments using alternative medicine 
can relieve some types of pain more effectively than placebo [40, 41]. Medicinal plants (MPs) 
have been used for centuries by many cultures to treat pain and this knowledge has been 
embraced by the pharmaceutical industry which has used it to synthesize and elaborate anal-
gesics commonly used in traditional Western treatments. The scientific verification process 
of this tradition is ongoing. The natural origin of MPs may lead to the false impression of 
innocuity and ample safety [42, 43], but despite presenting a wide therapeutic range, MPs are 
not exempt of adverse effects and interactions [44]; phytovigilance should be performed as for 
conventional medicines and should be sustained on a scientific basis regarding their toxicity 
and its allergenic potential [44]. Despite all this evidence, MPs use should not be discouraged, 
because for certain population, they are not only the adequate option but may be the only one 
available or affordable.
As it has been stated that the two main systems addressed in pain treatment are the routes 
involving COXs enzymes and opioids receptors and lately the inhibition of monoamines 
reuptake. Seeking for other options, lately, the endocannabinoid/vanilloid systems have 
also been studied regarding their effect on pain alleviation [45–47]. Although cannabis has 
proved to be useful in pain alleviation, there are two drawbacks for this option. First, can-
nabis is still a prohibited plant in many countries and second, as with many other plants, it 
is troublesome to identify the substance responsible for the action. To make matters worse, 
what raises concerns in this case is that tetrahydrocannabinol (THC) which is respon-
sible for pain alleviation is also responsible for the psychoactive effects of marijuana. THC 
is not the only natural occurring substances capable of agonizing the endocannabinoid 
receptors and efforts are being made to find synthetic derivatives with a safer profile. The 
entourage effect is also a problem when extracting substances from biological matrixes, 
as sometimes the final effect of a treatment depends on a group of substances and not just 
an isolated one.
Local anesthetics have also proven to be a useful tool in acute and chronic pain relief; lidocaine 
presents good results in this regard because of the rapid alleviation obtained after administra-
tion, though cardiovascular adverse effects should also be taken into consideration [48, 49]. 
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In newborns, sweet solutions have also presented analgesic properties showing promising 
results at very low cost and placing babies at minimum risk of side effects. There is also ongoing 
research over different forms of administration including patient-controlled analgesia, differ-
ent pharmaceutical forms for a more effective pain control as well as electrical techniques for 
disrupting pain signal.
3. Conclusion
It has been clearly stated that pain treatment is a challenge difficult to face. Health care teams 
have to articulate the resources available and patients’ needs in a particular scenario where 
previous experiences are sometimes difficult to extrapolate. This book intends to give those 
involved in pain management a proper idea of the tools available for pain relief, comprising 
pharmacological ones and adjuvant techniques, as well as presenting late research on analgesics, 
their benefits and security profile.
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